

Learner Notification

MED Learning Group
Fighting the Flu: Clinical Pearls for Healthcare Professionals
July 12, 2023 – July 12, 2024
Online

Acknowledgement of Financial Commercial Support

Genentech

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Facilitate a timely and accurate diagnosis of influenza in pediatric patients through the use of point-of-care testing methodologies.
2. Evaluate the mechanisms of action and clinical profiles of antiviral agents approved for the treatment of influenza in pediatric patients.
3. Incorporate evidence-based guidance for the selection of antiviral agents for pediatric patients with influenza into clinical practice.
4. Assess the results of studies supporting the use of antiviral treatments for influenza postexposure prophylaxis in pediatric patients.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
William A.	Fischer	Merck, Roche: Consultant, Janssen, Syneos: Adjudication Committee
Matthew	Frese	NA
Christina	Gallo	NA
Cindy	Lampner	NA
Felecia	Beachum	NA
Naomi	De Brito	NA
Lauren	Welch	NA
Aimee	Meissner	NA
Jo	Shultz	NA

Questions? Email Certificate@AmedcoEmail.com

